PT-141 Dosage Calculator: Units and Water for a 10mg Vial
The short answer
A 10mg PT-141 vial mixed with 2mL of bacteriostatic water is 5mg per mL, so 1mg is 0.2mL, or 20 units on a U-100 insulin syringe. Units measure volume, not milligrams: the same 1mg is 10 units with 1mL of water and 30 units with 3mL. The approved form of the same molecule, bremelanotide (Vyleesi), is a fixed 1.75mg autoinjector dose taken no more than once in 24 hours, with more than 8 doses a month not recommended, and that label does not apply to a research vial.
Best vendor for PT-141 right now: Amino Club, Code 100: 20% off.
Bureau Score 4.7, 0 of 1 independent tests passed (Finnrick). Compare every store. Reader codes were checked on the vendor's cart; offer terms are the vendor's and can change. Affiliate link: we earn a commission if you order. Laboratory research use only, not for human use.
This page does the arithmetic for a PT-141 vial and sets it beside what the approved bremelanotide label says. Unit figures are calculated from the formula below and were rechecked with exact fractions on 31 October 2026. Label figures come from the current Vyleesi prescribing information on DailyMed (label effective 13 November 2025), read on 31 October 2026, and every source is listed at the end.
PT-141 is a name for bremelanotide, the active ingredient in Vyleesi. Vyleesi is a ready-made solution in an autoinjector. A research vial sold as PT-141 is lyophilised powder that has to be mixed with bacteriostatic water, which is why a PT-141 dosage calculator is mostly a water-volume calculator.
PT-141 Units at a Glance: 10mg Vial With 2mL of Water
| Dose | Volume to draw | Units on a U-100 syringe |
|---|---|---|
| 0.5mg | 0.1mL | 10 units |
| 1mg | 0.2mL | 20 units |
| 1.75mg (the Vyleesi label dose, autoinjector only) | 0.35mL | 35 units |
| 2mg | 0.4mL | 40 units |
These doses are conversion inputs, not advice: the columns are there so a reader can turn a number they already hold into a syringe mark, and the only dose in the table with a regulatory label behind it is the 1.75mg Vyleesi dose, which is for the approved autoinjector. Mix the same vial with a different volume of water and every unit figure changes. The charts further down cover 5mg and 10mg vials at each common volume, and the matching Peptulator PT-141 calculator works out an odd vial strength or water volume.
The Three Numbers a PT-141 Calculation Needs
Every unit figure on this page comes from the same three inputs.
- Vial strength. The milligrams of lyophilised peptide stated on the label. Research vials are commonly 5mg or 10mg, and the charts below cover both.
- Diluent volume. The millilitres of bacteriostatic water added. This is a choice, not a property of the vial, and it is the input that most often goes unrecorded.
- Target dose. The milligrams intended per administration.
The first two produce concentration. Concentration and the third produce a volume, and volume produces a syringe mark. Skipping to a remembered unit number, without the diluent volume that generated it, is where the large errors come from.
The Formula, Written Out Once
First the concentration. Divide vial strength by the water added:
Concentration (mg/mL) = vial strength (mg) ÷ water added (mL)
Then the draw volume. Divide target dose by that concentration:
Draw volume (mL) = target dose (mg) ÷ concentration (mg/mL)
Then the syringe mark. A U-100 insulin syringe puts 100 units across 1mL, matching insulin sold at 100 units/mL, so one unit is 0.01mL:
Units = draw volume (mL) × 100
Worked example for a 10mg vial with 2mL of water: 10mg ÷ 2mL = 5mg/mL. A 1mg dose ÷ 5mg/mL = 0.2mL. 0.2mL × 100 = 20 units. The three steps collapse into one: units = dose (mg) × water (mL) × 100 ÷ vial strength (mg), so 1.75mg is 1.75 × 2 × 100 ÷ 10 = 35 units. The structure is identical to the tesamorelin calculation and to every other reconstituted peptide, which means one habit covers all of them: write the diluent volume on the vial label the moment you add it.
Where Bureau readers source PT-141
Amino Club and Pantheon are the two vendors on our scorecard that stock PT-141 consistently and publish a batch certificate of analysis on the product page. Concentration accuracy is the entire premise of a calculation page, and a vial that does not hold the milligrams printed on the label makes every figure below decorative. Research use only.
Check PT-141 at Amino Club Compare all vendorsWhat the Vyleesi Label Says, and Why It Does Not Apply to a Research Vial
The approved form of bremelanotide is Vyleesi, a single-dose prefilled autoinjector of 1.75mg in 0.3mL (about 5.8mg per mL) made by Cosette Pharmaceuticals, and the only bremelanotide label on DailyMed. The table is taken from its prescribing information, read on DailyMed on 31 October 2026.
| Label item | What the label says |
|---|---|
| Indication | Premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). Not indicated for HSDD in postmenopausal women or in men, and not indicated to enhance sexual performance. |
| Dose | 1.75mg subcutaneously in the abdomen or thigh, as needed, at least 45 minutes before anticipated sexual activity |
| Limits | No more than one dose within 24 hours. More than 8 doses a month is not recommended. |
| Product | 1.75mg/0.3mL clear solution in a single-dose autoinjector, self-administered |
| Blood pressure | Transient rises after each dose, with maximal increases of 6mmHg systolic and 3mmHg diastolic in clinical studies, peaking 2 to 4 hours after the dose and usually back to baseline within 12 hours. Contraindicated in uncontrolled hypertension or known cardiovascular disease. |
| Common side effects (pooled phase 3 trials, Vyleesi against placebo) | Nausea 40.0% against 1.3%, flushing 20.3% against 0.3%, injection site reactions 13.2% against 8.4%, headache 11.3% against 1.9% |
| Half-life | About 2.7 hours (range 1.9 to 4.0 hours). Median time to peak about 1 hour. |
The 1.75mg figure belongs to that autoinjector: a fixed 0.3mL volume of a solution of known strength. A research vial sold as PT-141 is not Vyleesi, is not covered by this label and has no FDA-approved dose. It is powder whose contents the Bureau cannot check beyond a supplier's certificate of analysis, mixed and drawn by hand. The trials enrolled premenopausal women aged 19 to 56, and the label says it is not indicated in men. So the 35 units that appear in the tables for 1.75mg is arithmetic for a 5mg/mL mix, not a label instruction.
The label describes bremelanotide as a melanocortin receptor agonist and says the mechanism by which it improves HSDD in women is unknown. The reported effect profile is covered in the PT-141 compound guide.
How Much Bac Water for a 10mg PT-141 Vial: Worked Chart
This chart is for a 10mg vial; the 5mg chart follows. All figures assume a U-100 insulin syringe.
| Water added | Concentration | 0.5mg | 1mg | 1.75mg (label dose) | 2mg |
|---|---|---|---|---|---|
| 1mL | 10mg/mL | 5 units | 10 units | 17.5 units | 20 units |
| 2mL | 5mg/mL | 10 units | 20 units | 35 units | 40 units |
| 3mL | 3.33mg/mL | 15 units | 30 units | 52.5 units | 60 units |
| 5mL | 2mg/mL | 25 units | 50 units | 87.5 units | 100 units |
Read down the 1mg column and the point of the page appears. The same 1mg dose is 10 units in the first row and 50 units in the last. Both are right, because both describe 1mg. Anyone who memorises a unit number without the diluent volume attached has memorised nothing transferable.
Two millilitres is the volume the Bureau's tables and the Peptulator calculator use for a 10mg vial, because it gives round numbers: 0.5mg, 1mg, 1.75mg and 2mg land on 10, 20, 35 and 40 units. At 1mL, 3mL and 5mL the 1.75mg column falls on a half unit (17.5, 52.5 and 87.5), between the marks of a syringe graduated in whole units.
Worked Chart: 5mg PT-141 Vial
| Water added | Concentration | 0.5mg | 1mg | 1.75mg (label dose) | 2mg |
|---|---|---|---|---|---|
| 1mL | 5mg/mL | 10 units | 20 units | 35 units | 40 units |
| 2mL | 2.5mg/mL | 20 units | 40 units | 70 units | 80 units |
| 2.5mL | 2mg/mL | 25 units | 50 units | 87.5 units | 100 units |
Note that a 5mg vial with 1mL produces the same concentration as a 10mg vial with 2mL, and therefore the same unit marks. Concentration is the only thing the syringe knows about. Vial strength decides how many doses you get, not how far to pull the plunger.
Run your own vial through it
Vial strength, bacteriostatic water added, target dose, and the exact syringe mark comes out the other side. Faster than the chart if your vial is an odd strength, and it shows the working rather than just the answer.
Open the dosing calculator peptulator.com, the Bureau's independent toolDoses Per Vial, and Why That Sets the Water Volume
The Vyleesi label dose is taken as needed rather than on a standing schedule, which makes doses per vial a more useful planning figure here than for a daily compound. The table counts whole doses; the remainder is less than one full dose.
| Vial | At 0.5mg | At 1mg | At 1.75mg | At 2mg |
|---|---|---|---|---|
| 5mg | 10 doses | 5 doses | 2 full doses (2.9) | 2 full doses (2.5) |
| 10mg | 20 doses | 10 doses | 5 full doses (5.7) | 5 doses |
This is where the diluent choice becomes a real decision rather than a preference. A reconstituted research vial has no label shelf life the Bureau can cite, so pick the water volume against how quickly the vial will realistically be used, not against the finest division the syringe can theoretically read. The storage guide covers keeping reconstituted peptides in more detail.
PT-141 Reconstitution: Choosing the Diluent Volume
Water does not change how much peptide is in the vial. It changes how finely it can be divided, and the tradeoff runs both ways.
Too little water
A 10mg vial with 0.5mL sits at 20mg/mL, putting a 1mg dose at 5 units. At that concentration one unit is 0.2mg, so a slip of a single unit is 20 percent of a 1mg dose.
Too much water
A 10mg vial with 5mL puts a 2mg dose at 100 units, the entire barrel of a 1mL U-100 syringe. Anything above 2mg then needs a second draw.
The middle
For a 10mg vial, 2mL to 3mL puts the doses in the tables between 10 and 60 units, in the middle of the syringe, where one unit is a small share of the dose rather than a large one. The handling sequence itself, from swabbing the stopper to directing water down the vial wall rather than onto the powder, is covered in the reconstitution guide, and the diluent choice in the bacteriostatic water guide.
The Errors That Cost a Factor of Ten
The errors that matter most in a calculation like this are arithmetic and labelling errors, and they cluster in four places.
- The unrecorded diluent volume. A vial reconstituted last month with an unremembered volume cannot be dosed from at all, because there is no way to recover the concentration by looking at it. Write the volume and the date on the vial.
- Milligrams read as micrograms. A protocol written in mcg beside a vial labelled in mg invites a thousandfold slip. 1mg is 1000mcg. A protocol quoting 500mcg means 0.5mg, not 500mg.
- Assuming the syringe scale is a dose scale. Units are volume. The same 20 unit draw is 0.5mg, 1mg or 2mg depending only on the water. There is no such thing as a correct unit figure for PT-141 in the abstract.
- Carrying a number between vial strengths. Switching from a 10mg vial to a 5mg vial while keeping the same water volume and the same unit mark halves the dose silently. The plunger looks identical in both cases.
None of these are exotic, and the habit that guards against most of them is writing the vial strength, the diluent volume and the date on the label before the syringe comes out. The injection mechanics themselves are covered in the injection guide.
PT-141 at Pantheon. The second stocked source the Bureau scores for this compound, listed with a batch certificate of analysis. Worth comparing on price per milligram before committing, since dose-per-vial arithmetic is really cost arithmetic. Research use only.
Check PT-141 at PantheonWhat the Calculation Cannot Tell You
A calculator produces a number from a label, and assumes the label is accurate. That assumption is the weakest link in the sequence. A vial holding 7mg rather than the 10mg printed on it makes every figure on this page wrong by 30 percent, and no amount of careful syringe reading recovers it. That is the argument for a published batch certificate of analysis rather than a marketing claim about purity.
The calculation also says nothing about whether a dose is advisable. The Vyleesi label lists a transient rise in blood pressure after each dose, contraindicates it in uncontrolled hypertension or known cardiovascular disease, and reports nausea in 40.0% of women on Vyleesi against 1.3% on placebo in the pooled phase 3 trials. Nausea was highest after the first dose (21% of patients) and fell to about 3% after later doses. Anyone reading a dosing chart should read the safety profile alongside it rather than instead of it. Nothing here is medical advice.
Finally, the calculation says nothing about legal status. PT-141 sold as a research chemical is not the approved drug, whatever the approved status of bremelanotide as a finished product. On 30 October 2026 HHS published an interim enforcement discretion policy for 503A compounding of six named peptides (BPC-157, epitalon, KPV, MOTS-c, semax and TB-500); bremelanotide is not on that list. The legal status guide covers what the research use only designation does and does not mean.
Key Takeaways
- Concentration is vial strength divided by water added, and it is the only thing the syringe scale responds to
- Units = dose (mg) × water (mL) × 100 ÷ vial strength (mg) on a U-100 insulin syringe, where one unit is 0.01mL
- A 10mg vial with 2mL gives 5mg/mL, putting 0.5mg at 10 units, 1mg at 20 units, 1.75mg at 35 units and 2mg at 40 units
- A 5mg vial with 1mL gives the same concentration and therefore the same unit marks as a 10mg vial with 2mL
- The Vyleesi label dose is 1.75mg from the autoinjector, no more than once in 24 hours, with more than 8 doses a month not recommended; a research vial is not Vyleesi and the label dose does not transfer to it
- A 10mg vial holds 20 doses of 0.5mg, 10 of 1mg and 5 full doses of 1.75mg or 2mg
- Write the vial strength, diluent volume and date on the vial label before drawing anything
- Every figure here assumes the label is accurate, which is why a batch certificate of analysis matters more than the arithmetic
Frequently Asked Questions
How many units of PT-141 is 1mg?
On a U-100 insulin syringe, 1mg is 20 units (0.2mL) when a 10mg vial is mixed with 2mL of bacteriostatic water, which gives 5mg per mL. With 1mL of water the same 1mg is 10 units, with 3mL it is 30 units and with 5mL it is 50 units. Units measure volume, so the count depends on the water added, not on the peptide.
How much bac water for a 10mg PT-141 vial?
Any volume of bacteriostatic water (bac water) works if the arithmetic follows it. Two millilitres gives 5mg per mL, and 0.5mg, 1mg and 2mg then draw 10, 20 and 40 units. One millilitre gives 10mg per mL (5, 10 and 20 units for the same doses) and 3mL gives 3.33mg per mL (15, 30 and 60 units). Write the water volume on the vial when it goes in, because the vial cannot tell you later.
What is the bremelanotide dosage on the Vyleesi label?
The Vyleesi label gives 1.75mg injected under the skin of the abdomen or thigh, as needed, at least 45 minutes before anticipated sexual activity. It says no more than one dose within 24 hours and that more than 8 doses a month is not recommended. The product is a prefilled autoinjector holding 1.75mg in 0.3mL, indicated for premenopausal women with acquired, generalized hypoactive sexual desire disorder. The label says it is not indicated in men.
Is a PT-141 research vial the same as Vyleesi?
No. PT-141 is a name for bremelanotide, the active ingredient in Vyleesi, but a research vial is a different product from the approved autoinjector and is not covered by the Vyleesi label. The 1.75mg label dose belongs to the autoinjector only. Research vials are sold for laboratory use, and the printed milligrams are the supplier's claim, which is why a batch certificate of analysis matters.
How many doses are in a 10mg PT-141 vial?
By arithmetic, a 10mg vial holds 20 doses of 0.5mg, 10 doses of 1mg, 5 full doses of 1.75mg (5.7, with a part dose left over) and 5 doses of 2mg. A 5mg vial holds half as many. The water volume changes how finely each dose is measured, not how many doses the vial holds.
How long before activity is PT-141 taken, and how long does it last?
The Vyleesi label says to take it at least 45 minutes before anticipated sexual activity. Plasma levels peak at a median of about 1 hour and the half-life is about 2.7 hours (range 1.9 to 4.0 hours). The label states that the duration of efficacy after each dose is unknown.
What side effects and warnings does the Vyleesi label list?
In the pooled phase 3 trials, nausea was reported by 40.0% of women on Vyleesi against 1.3% on placebo, flushing by 20.3% against 0.3%, injection site reactions by 13.2% against 8.4% and headache by 11.3% against 1.9%. The label says Vyleesi transiently raises blood pressure after each dose, with maximal increases of 6mmHg systolic and 3mmHg diastolic in studies, and it is contraindicated in uncontrolled hypertension or known cardiovascular disease. It also reports focal hyperpigmentation in 1% of women on up to 8 doses a month.
Why does the same number of units give a different PT-141 dose?
Because the markings on an insulin syringe measure volume, not peptide. One unit on a U-100 syringe is 0.01mL whatever is in the barrel. The dose that volume carries is set by concentration, which is vial strength divided by the water added, so changing the water changes every unit figure. A unit figure without its water volume cannot be turned back into milligrams.
Sources
- Vyleesi (bremelanotide) injection prescribing information (sections 1, 2.1, 3, 4, 5.1, 5.2, 6.1, 12.1, 12.3 and 14), Cosette Pharmaceuticals, label effective 13 November 2025: Vyleesi on DailyMed. Checked 31 October 2026.
- Humalog (insulin lispro) injection prescribing information (section 3, 100 units/mL, U-100), Eli Lilly and Company, label effective 16 June 2026: Humalog on DailyMed. Checked 31 October 2026.
- National Library of Medicine, PubChem compound record for bremelanotide (CID 9941379), listing PT-141 and Vyleesi among its names. Checked 31 October 2026.
- HHS, Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, Appendix A, notice 2026-22192, 91 FR 68526, published 30 October 2026: Federal Register. Checked 31 October 2026.
- Peptulator, PT-141 dosage calculator, the Bureau's independent tool; its 10mg vial with 2mL of water figures match the tables here. Checked 31 October 2026.
Label figures are from the US Vyleesi label effective 13 November 2025, read on DailyMed on 31 October 2026. Labels change; the leaflet in your box wins. Unit figures are arithmetic, recomputed with exact fractions on 31 October 2026. Educational content, not medical advice.
Medical disclaimer
This article is for educational and informational purposes only and is not medical advice. PT-141 sold as a research chemical is not approved for human therapeutic use and is supplied for laboratory research only. Nothing here is a recommendation to obtain or administer any compound. The figures described are reconstitution arithmetic and reported market conventions documented for reference, alongside the published label figures for the approved bremelanotide product, and they are included to describe what exists rather than to guide use. Consult a qualified clinician before making any decision about your health.
Not sure which of these you actually need?
Answer five questions about your goal, experience and budget and the Stack Builder shows you a matched research protocol on screen, with the compounds, cycle shape and vendor picks from the vendors we score.
Build your stack, 2 minutes